Slide 1: Q2 FY25 Earnings Presentation
Q2 FY25 Earnings Presentation August 7, 2025 © Solventum 2025. All rights reserved.
Slide 2: Forward-looking statements and use of document
Forward-looking statements and use of document This presentation and other materials Solventum has filed or will file with the U.S. Securities & Exchange Commission (“SEC”) (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events a
Slide 3: Solventum value creation formula
Solventum value creation formula Attractive set up diverse businesses, attractive markets and strong brands Foundational + enhancements mission, talent, culture, innovation engine (commercial and R&D) market selection and growth drivers – enable sales growth, + Strategic clarity margin expansion and
Slide 4: Key Messages for the Quarter
Key Messages Positive for the Quarter Solid Q2 Momentum Performance Across Segments Continued Raised Progress on 2025 Separation Guidance © Solventum 2025. All rights reserved. 4 2See non-GAAP financial measures and reconciliation schedules in the appendix of this document.
Slide 5: Q2 FY25 Financial summary
Q2 FY25 Financial summary Segment sales Dental Solutions $338M Key Metrics +2.3% Reported +0.7% Organic GAAP Non-GAAP2 Health Information Operating Systems TOTAL SOLVENTUM1 MedSurg margin 9.9% 21.9% $339M $2,161M $1,218M +3.4% Reported +3.9% Y/Y Reported +4.8% Reported +3.2% Organic +2.8% Y/Y Organi
Slide 6: MedSurg summary
MedSurg summary AWC $467M | 38% +1.7% Y/Y Rep +0.8% Y/Y Org $1,218M Q2 financial results +4.8% Y/Y Reported +3.9% Y/Y Organic IP&SS Q2 FY25 Q2 FY24 Y/Y $750M | 62% +6.9% Y/Y Rep +5.9% Y/Y Org Reported +4.8% Net sales $1,218M $1,162M Organic +3.9% Tegaderm CHG Chlorhexidine Gluconate IV Securement Dr
Slide 7: Dental Solutions summary
Dental Solutions summary Clarity Precision Grip Attachments The first and only 3D printed aligner Q2 financial results attachments, ClarityTM Precision Grip Attachments deliver excellent predictability in orthodontic forces, Q2 FY25 Q2 FY24 Y/Y due to no excess cured composite, and reduce procedure
Slide 8: Health Information Systems summary
Health Information Systems summary Solventum 360 Encompass System Latest generation coding solution Q2 financial results combines coding and reimbursement processes along with workflow improvements Q2 FY25 Q2 FY24 Y/Y Reported +3.4% Net sales $339M $328M Organic +3.2% • Growth driven by continued ad
Slide 9: Purification & Filtration summary
3M Liqui-Cel Purification & Filtration summary Membrane Contactors Boosts process efficiency of ultra- Q2 financial results pure water treatment systems by removing dissolved gases; supports rigorous quality manufacturing Q2 FY25 Q2 FY24 Y/Y specifications across multiple industrial applications Rep
Slide 10: FY2025 financial guidance and considerations
FY2025 financial guidance Additional considerations and considerations FX impact ~50bps favorable prior assumption for neutral impact on reported sales Incremental Tariff Impact: Lower estimate driven by latest tariff rates Organic sales growth +2.0% to +3.0% ~$60M to $80M pre-tax headwind; equates
Slide 11: Appendix
Appendix © Solventum 2025. All rights reserved. 11
Slide 12: Non-GAAP financial measures
Non-GAAP financial measures In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adj
Slide 13: Q2 FY25 non-GAAP reconciliation & free cash flow
Q2 FY25 non-GAAP reconciliation & free cash flow Spin-off & separation- Certain litigation- Sale of Purification ($ Millions, except per share data) Q2 FY25 GAAP Amortization Restructuring related costs related costs and Filtration-related Q2 FY25 non-GAAP Net sales 2,161 2,161 Gross margin 1,175 1
Slide 14: Glossary and definitions
Glossary and definitions Abbreviation Elaboration Organic sales growth AWC Advanced Wound Care Total net sales less the impacts of foreign currency and sales from business acquisitions or divestitures for the first 12 months post-transaction FCF Free cash flow Adjusted operating income Operating inc